![ADDING MULTIMEDIA Exelixis Announces FDA Approval of CABOMETYX™ ( Cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy | Business Wire ADDING MULTIMEDIA Exelixis Announces FDA Approval of CABOMETYX™ ( Cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy | Business Wire](https://mms.businesswire.com/media/20160425006329/en/521197/5/640.jpg)
ADDING MULTIMEDIA Exelixis Announces FDA Approval of CABOMETYX™ ( Cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy | Business Wire
![Cabometyx (cabozantinib) for Treatment of Patients with Advanced Renal Cell Carcinoma - Clinical Trials Arena Cabometyx (cabozantinib) for Treatment of Patients with Advanced Renal Cell Carcinoma - Clinical Trials Arena](https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-115.jpg)
Cabometyx (cabozantinib) for Treatment of Patients with Advanced Renal Cell Carcinoma - Clinical Trials Arena
![ADDING MULTIMEDIA Exelixis Announces FDA Approval of CABOMETYX™ ( Cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy | Business Wire ADDING MULTIMEDIA Exelixis Announces FDA Approval of CABOMETYX™ ( Cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy | Business Wire](https://mms.businesswire.com/media/20160425006329/en/520945/5/CABOMETYX_40_mg.jpg)
ADDING MULTIMEDIA Exelixis Announces FDA Approval of CABOMETYX™ ( Cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy | Business Wire
![Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma | Business Wire Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma | Business Wire](https://mms.businesswire.com/media/20190114005830/en/699885/22/3685095_Cabometyx_R_mg_RGB.jpg)
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma | Business Wire
![ADDING MULTIMEDIA Exelixis Announces FDA Approval of CABOMETYX™ ( Cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy | Business Wire ADDING MULTIMEDIA Exelixis Announces FDA Approval of CABOMETYX™ ( Cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy | Business Wire](https://mms.businesswire.com/media/20160425006329/en/520946/5/40_mg_Individual.jpg)